Gabapentin Tablet
Product Images NDC 71205-514

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-514). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-514-60 (Gabapentin 800mg 30tab)

Label for Gabapentin 800 mg tablets by Proficient Rx LP, package size of 90 tablets. The film-coated tablets have a modified capsule shape, are biconvex, and scored with markings 'SG' and '178'. Manufactured by ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period, while the y-axis represents mean pain scores ranging from 0 to 10. Gabapentin shows a decreasing trend in pain scores compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration phase and a 4-week fixed dose phase. The y-axis shows mean pain scores from 0 to 10, illustrating a decrease in pain scores for gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Each study compares placebo (PBO) response rates with Gabapentin (GBP) at various dosages (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2). Percentages of responders are indicated above each bar, with statistical significance markers noted ('**' for p<0.01, '***' for p<0.001).*

FDA Label Image

Image-04 (Image 04)

A formula table illustrating the calculation of creatinine clearance (CLCr). It uses variables including age in years, weight in kilograms, serum creatinine in mg/dL, and a gender adjustment factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing the molecular layout with a cyclohexane ring attached to amino and carboxyl functional groups.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot comparing percentage difference by daily gabapentin dose (mg) across three studies labeled as Study a, Study b, and Study c. The x-axis represents daily dose in milligrams (600 to 1800 mg) and the y-axis shows difference percentage (0 to 22%). Data points from each study are plotted at various dose levels with corresponding difference percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.